Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis

References

• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):1–850.
   PubMed Web of Science ®Google Scholar
• Korman NJ, Zhao Y, Pike J, et al. Increased severity of itching, pain, and scaling in psoriasis patients is associated with increased disease severity, reduced quality of life, and reduced work productivity. Dermatol Online J. 2015;21(10):13030/qt1x16v3dg.
   Google Scholar
• de Korte J, Sprangers MA, Mombers FM, et al. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9(2):140–7.
   PubMed Web of Science ®Google Scholar
• Bhutani T, Patel T, Koo B, et al. A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions. J Am Acad Dermatol. 2013;69(2):e79–e88.
   PubMed Web of Science ®Google Scholar
• Nowowiejska J, Baran A, Grabowska P, et al. Assessment of life quality, stress and physical activity among patients with psoriasis. Dermatol Ther. 2022;12(2):395–406.
   Web of Science ®Google Scholar
• Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes. 2009;7:62.
   PubMed Web of Science ®Google Scholar
• Zhong H, Yang H, Mao Z, et al. Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study. Health Qual Life Outcomes. 2021;19(1):271.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288.
   PubMed Web of Science ®Google Scholar
• ILUMYA® (tildrakizumab-asmn). [full prescribing information]. Cranbury (NJ): Sun Pharmaceutical Industries, Inc.
   Google Scholar
• Blauvelt A, Sofen H, Papp K, et al. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2019;33(12):2305–2312.
   PubMed Web of Science ®Google Scholar
• Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the corrona psoriasis registry. BMJ Open. 2019;9(4):e027535.
   PubMed Web of Science ®Google Scholar
• Meneguin S, de Godoy NA, Pollo CF, et al. Quality of life of patients living with psoriasis: a qualitative study. BMC Dermatol. 2020;20(1):22.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Lacour JP, Bewley A, Hammond E, et al. Association between patient- and physician-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with biologics in real life (PSO-BIO-REAL). Dermatol Ther. 2020;10(5):1099–1109.
   Web of Science ®Google Scholar
• Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2015;26(3):235–239.
   PubMed Web of Science ®Google Scholar
• Ryan C, Puig L, Zema C, et al. The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis. J Am Acad Dermatol. 2023;88(1):169–172.
   PubMed Web of Science ®Google Scholar
• Gerdes S, Korber A, Biermann M, et al. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. J Dermatolog Treat. 2020;31(5):470–475.
   PubMed Web of Science ®Google Scholar
• Puig L, Thom H, Mollon P, et al. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213–220.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Reich K, Crowley JJ, et al. Disease activity and treatment efficacy using patient-level psoriasis area and severity index scores from tildrakizumab phase 3 clinical trials. J Dermatolog Treat. 2022;33(1):219–228.
   PubMed Web of Science ®Google Scholar
• Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–1774.
   PubMed Web of Science ®Google Scholar
• Spandonaro F, Altomare G, Berardesca E, et al. Health-related quality of life in psoriasis: an analysis of psocare project patients. G Ital Dermatol Venereol. 2011;146(3):169–177.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Niiro H, Ootaki K, et al. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44–52.
   PubMed Web of Science ®Google Scholar
• Augustin M, Lambert J, Zema C, et al. Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials. JAMA Dermatol. 2020;156(12):1344–1353.
   PubMed Web of Science ®Google Scholar
• Miyagi T, Kanai Y, Murotani K, et al. Itch as a critical factor in impaired health-related quality of life in patients with plaque psoriasis achieving clear or almost-clear skin: analysis of the single-arm, open-label, multicenter, prospective ProLOGUE study. JAAD Int. 2022;8:146–153.
   PubMedGoogle Scholar